RESEARCH TRIANGLE PARK, N.C. — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. “We have an...
finance News
NEW HAVEN, Conn. and LEUVEN, Belgium – Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), along with CD3 and LICR at KU Leuven, announced that they have entered into an exclusive global license and research agreement to develop and commercialize first-in-class TRPM3 antagonists to address...
CAMBRIDGE, Mass. – bluebird bio, Inc. (NASDAQ: BLUE) today announced the company has completed the tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc., an independent, publicly-traded company. bluebird bio will continue its work focused on severe genetic disease, with three near-term opportunities to bring transformative gene...
CAMBRIDGE, Mass. – bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress. “For over ten years, bluebird bio has been pioneering gene therapies for patients with rare diseases and cancer, and our...
NEW YORK – Quest Diagnostics subsidiary Blueprint Genetics said on Thursday that it has partnered with the Helsinki Biobank and Helsinki University Hospital for a research initiative called Rare3k that aims to develop algorithms to accelerate the identification of patients who could benefit from genetic testing for certain rare diseases....
Cambridge, Mass. — Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that, effective April 1, 2023, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 5,933 shares of its...
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated this...
STAMFORD, Conn. — Cara Therapeutics, Inc. today announced it will focus its resources on the oral difelikefalin Phase 2/3 clinical program in notalgia paresthetica (NP) and significantly reduce its operating expenses. These measures will extend the Company’s cash runway into 2026, enabling the expected completion of the NP clinical program....
– Series A financing co-led by Third Rock Ventures, RTW and Perceptive Xontogeny Venture Fund, and includes new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, T. Rowe Price, Cormorant Asset Management and Piper Heartland with participation from existing seed investors
– Initial Phase 1 results with CARGO’s CD22 CAR T-cell therapy demonstrated durable complete responses in greater than 50% of patients with large B-cell lymphoma (LBCL) that is relapsed/refractory (R/R) to CD19 CAR T-cell therapy. CARGO plans to commence Phase 2 pivotal trial of CRG-022 (CD22 CAR) in mid-2023 in patients with LBCL that is R/R to CD19 CAR T-cell therapy
– CD22 CAR has been granted Breakthrough Therapy Designation by the FDA, which is intended to expedite the development and review of drugs for patients with significant unmet need
– CARGO Therapeutics was launched in 2021 by Samsara BioCapital in collaboration with CAR T pioneers, Crystal Mackall, MD, and Robbie Majzner, MD, and accomplished cancer advocate, Nancy Goodman, JD
BOSTON – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. (“Astria” or the “Company”). The name Astria originates from the Greek word for star, reflecting the Company’s commitment to having patients serve as guiding stars....